Cancer Pharmacogenomics: DNA Genotyping and Gene Expression Profiling to Identify Molecular Determinants of Chemosensitivity

REFERENCES

• Bieche I., Laurendeau I., Tozlu S., Olivi M., Vidaud D., Lidereau R., Vidaud M. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res. 1999; 59: 2759–2765
   PubMed Web of Science ®Google Scholar
• Bild A. H., Yao G., Chang J. T., Wang W., Potti A., Chasse D., Joshi M.-B., Harpole D., Lancaster J. M., Berchuck A., Olson J. A., Marks J. R., Dressman H. K., West M., Nevins J. R. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353–357
   PubMed Web of Science ®Google Scholar
• Borgna J. L., Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem. 1981; 256: 859–868
   PubMed Web of Science ®Google Scholar
• Bussey K. J., Chin K., Lababidi S., Reimers M., Reinhold W. C., Kuo W.-L., Gwadry F., Ajay F., Kouros-Mehr H., Fridlyand J., Jain A., Collins C., Nishizuka S., Tonon G., Roschke A., Gehlhaus K., Kirsch I., Scudiero D. A., Gray J. W., Weinstein J. N. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol. Cancer Ther. 2006; 5: 853–867
   PubMed Web of Science ®Google Scholar
• Buyse M., Loi S., van't Veer L., Viale G., Delorenzi M., Glas A. M., Saghatchian d'Assignies M., Bergh J., Lidereau R., Ellis P., Harris A., Bogaerts J., Therasse P., Floore A., Amakrane M., Piette F., Rutgers E., Sotiriou C., Cardoso F., Piccart M. J. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst. 2006; 98: 1183–1192
   PubMed Web of Science ®Google Scholar
• Capizzi R. L., Bertino J. R., Handschumacher R. E. L-asparaginase. Annu. Rev. Med. 1970; 21: 433–444
   PubMed Web of Science ®Google Scholar
• Chang J. C., Wooten E. C., Tsimelzon A., Hilsenbeck S. G., Gutierrez M. C., Elledge R., Mohsin S., Osborne C. K., Chamness G. C., Allred D. C., O'Connell P. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362–369
   PubMed Web of Science ®Google Scholar
• Cooney D. A., Handschumacher R. E. L-asparaginase and L-asparagine metabolism. Annu. Rev. Pharmacol. 1970; 10: 421–440
   PubMedGoogle Scholar
• Cronin M., Pho M., Dutta D., Stephans J. C., Shak S., Kiefer M. C., Esteban J. M., Baker J. B. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am. J. Pathol. 2004; 164: 35–42
   PubMed Web of Science ®Google Scholar
• Desta Z., Ward B. A., Soukhova N. V., Flockhart D. A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 2004; 310: 1062–1075
   PubMed Web of Science ®Google Scholar
• Dolan M. E., Newbold K. G., Nagasubramanian R., Wu X., Ratain M. J., Cook E. H., Jr., Badner J. A. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 2004; 64: 4353–4356
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaboration Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687–1717
   PubMed Web of Science ®Google Scholar
• Glas A. M., Floore A., Delahaye L. J., Witteveen A. T., Pover R. C., Bakx N, Lahti-Domenici J. S., Bruinsma T. J., Warmoes M. O., Bernards R., Wessels L. F., Van't Veer L. J. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006; 7: 278
   PubMed Web of Science ®Google Scholar
• Goekkurt E., Hoehn S., Wolschke C., Wittmer C., Stueber C., Hossfeld D. K., Stoehlmacher J. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients. Br. J. Cancer 2006; 94: 281–286
   PubMed Web of Science ®Google Scholar
• Goetz M. P., Kamal A., Ames M. M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin. Pharmacol. Ther. 2007, (In press, DOI: 10.1038/sj.clpt.6100367.)
   PubMed Web of Science ®Google Scholar
• Goetz M. P., Knox S. K., Suman V. J., Rae J. M., Safgren S. L., Ames M. M., Visscher D. W., Reynolds C., Couch F. J., Lingle W. L., Weinshilboum R. M., Fritcher E. G., Nibbe A. M., Desta Z., Nguyen A., Flockhart D. A., Perez E. A., Ingle J. N. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 2007; 101: 113–121
   PubMed Web of Science ®Google Scholar
• Goetz M. P., Rae J. M., Suman V. J., Safgren S. L., Ames M. M., Visscher D. W., Reynolds C., Couch F. J., Lingle W. L., Flockhart D. A., Desta Z., Perez E. A., Ingle J. N. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 2005; 23: 9312–9318
   PubMed Web of Science ®Google Scholar
• Horie N., Aiba H., Oguro K., Hojo H., Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 1995; 20: 191–197
   PubMed Web of Science ®Google Scholar
• Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J. F., Hoctin-Boes G., Houghton J., Locker G. Y., Tobias J. S. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 60–62
   PubMed Web of Science ®Google Scholar
• Huang R. S., Duan A., Shukla S. J., Kistner E. O., Clark T. A., Chen T. X., Schweitzer A. C., Blume J. E., Dolan M. E. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am. J. Hum. Genet. 2007; 81: 427–437
   PubMed Web of Science ®Google Scholar
• Ingle J. N., Suman V. J., Mailliard J. A., Kugler J. W., Krook J. E., Michalak J. C., Pisansky T. M., Wold L. E., Donohue J. H., Goetz M. P., Perez E. A. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res. Treat. 2006; 98: 217–222
   PubMed Web of Science ®Google Scholar
• Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K. H., Skaar T., Storniolo A. M., Li L., Araba A., Blanchard R., Nguyen A., Ullmer L., Hayden J., Lemler S., Weinshilboum R. M., Rae J. M., Hayes D. F., Flockhart D. A. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 2005; 97: 30–39
   PubMed Web of Science ®Google Scholar
• Johnson M. D., Zuo H., Lee K. H, Trebley J. P., Rae J. M., Weatherman R. V., Desta Z., Flockhart D. A., Skaar T. C. Pharmacological characterization of 4‐hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 2004; 85: 151–159
   PubMed Web of Science ®Google Scholar
• Johnston P. G., Mick R., Recant W., Behan K. A., Dolan M. E., Ratain M. J., Beckmann E., Weichselbaum R. R., Allegra C. J., Vokes E. E. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J. Natl. Cancer Inst. 1997; 89: 308–313
   PubMed Web of Science ®Google Scholar
• Kawakami K., Omura K., Kanehira E., Watanabe Y. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 1999; 19: 3249–3252
   PubMed Web of Science ®Google Scholar
• Kobayashi S., Boggon T. J., Dayaram T., Janne P. A., Kocher O., Meyerson M., Johnson B. E., Eck M. J., Tenen D. G., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2005; 352: 786–792
   PubMed Web of Science ®Google Scholar
• Kristiansen G., Yu Y., Petersen S., Kaufmann O., Schluns K., Dietel M., Petersen I. Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. Eur. J. Cancer 2001; 37: 1089–1095
   PubMed Web of Science ®Google Scholar
• Lee J. K., Havaleshko D. M., Cho H., Weinstein J. N., Kaldjian E. P., Karpovich J., Grimshaw A., Theodorescu D. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl. Acad. Sci. USA 2007; 104: 13086–13091
   PubMed Web of Science ®Google Scholar
• Lim H.-S., Ju Lee H., Seok Lee K., Sook Lee E., Jang I.-J., Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol. 2007; 25: 3837–3845
   PubMed Web of Science ®Google Scholar
• Lonning P. E., Lien E. A., Lundgren S., Kvinnsland S. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin. Pharmacokinet. 1992; 22: 327–358
   PubMed Web of Science ®Google Scholar
• Lynch T. J., Bell D. W., Sordella R, Gurubhagavatula S., Okimoto R. A., Brannigan B. W., Harris P. L., Haserlat S. M., Supko J. G., Haluska F. G., Louis D. N., Christiani D. C., Settleman J., Haber D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350: 2129–2139
   PubMed Web of Science ®Google Scholar
• Ma X. J., Wang Z., Ryan P. D., Isakoff S. J., Barmettler A., Fuller A., Muir B., Mohapatra G., Salunga R., Tuggle J. T., Tran Y., Tran D., Tassin A., Amon P., Wang W., Wang W., Enright E., Stecker K., Estepa-Sabal E., Smith B., Younger J., Balis U., Michaelson J., Bhan A., Habin K., Baer T. M., Brugge J., Haber D. A., Erlander M. G., Sgroi D. C. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5: 607–616
   PubMed Web of Science ®Google Scholar
• Martin Y. N., Salavaggione O. E., Eckloff B. W., Wieben E. D., Schaid D. J., Weinshilboum R. M. Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenet. Genomics 2006; 16: 265–277
   PubMed Web of Science ®Google Scholar
• Mathijssen R. H., Marsh S., Karlsson M. O., Xie R., Baker S. D., Verweij J., Sparreboom A., McLeod H. L. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res. 2003; 9: 3246–3253
   PubMed Web of Science ®Google Scholar
• Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F. L., Walker M. G., Watson D., Park T., Hiller W., Fisher E. R., Wickerham D. L., Bryant J., Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004; 351: 2817–2826
   PubMed Web of Science ®Google Scholar
• Paik S., Tang G., Shak S., Kim C., Baker J., Kim W., Cronin M., Baehner F. L., Watson D., Bryant J., Costantino J. P., Geyer C. E., Jr., Wickerham D. L., Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 2006; 24: 3726–3734
   PubMed Web of Science ®Google Scholar
• Potti A., Dressman H. K., Bild A., Riedel R. F., Chan G., Sayer R., Cragun J., Cottrill H., Kelley M. J., Petersen R., Harpole D., Marks J., Berchuck A., Ginsburg G. S., Febbo P., Lancaster J., Nevins J. R. Genomic signatures to guide the use of chemotherapeutics. Nat. Med. 2006; 12: 1294–1300
   PubMed Web of Science ®Google Scholar
• Pui C.-H., Evans W. E. Acute Lymphoblastic Leukemia.. N Engl. J. Med. 1998; 339: 605–615
   PubMed Web of Science ®Google Scholar
• Pui C.-H., Sandlund J. T., Pei D., Campana D., Rivera G. K., Ribeiro R. C., Rubnitz J. E., Razzouk B. I., Howard S. C., Hudson M. M., Cheng C., Kun L. E., Raimondi S. C., Behm F. G., Downing J. R., Relling M. V., Evans W. E. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104: 2690–2696
   PubMed Web of Science ®Google Scholar
• Pui C. H., Gaynon P. S., Boyett J. M., Chessells J. M., Baruchel A., Kamps W., Silverman L. B., Biondi A., Harms D. O., Vilmer E., Schrappe M., Camitta B. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359: 1909–1915
   PubMed Web of Science ®Google Scholar
• Rocha J. C. C., Cheng C., Liu W., Kishi S., Das S., Cook E. H., Sandlund J. T., Rubnitz J., Ribeiro R., Campana D., Pui C.-H., Evans W. E., Relling M. V. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105: 4752–4758
   PubMed Web of Science ®Google Scholar
• Ross D. T., Scherf U., Eisen M. B., Perou C. M., Rees C., Spellman P., Iyer V., Jeffrey S. S., Van de Rijn M., Waltham M., Pergamenschikov A., Lee J. C. F., Lashkari D., Shalon D., Myers T. G., Weinstein J. N., Botstein D., Brown P. O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 2000; 24: 227–235
   PubMed Web of Science ®Google Scholar
• Scherf U., Ross D. T., Waltham M., Smith L. H., Lee J. K., Tanabe L., Kohn K. W., Reinhold W. C., Myers T. G., Andrews D. T., Scudiero D. A., Eisen M. B., Sausville E. A., Pommier Y., Botstein D., Brown P. O., AWeinstein J. N. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 2000; 24: 236–244
   PubMed Web of Science ®Google Scholar
• Staunton J. E., Slonim D. K., Coller H. A., Tamayo P., Angelo M. J., Park J., Scherf U., Lee J. K., Reinhold W. O., Weinstein J. N., Mesirov J. P., Lander E. S., Golub T. R. Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA 2001; 98: 10787–10792
   PubMed Web of Science ®Google Scholar
• Stearns V., Johnson M. D., Rae J. M., Morocho A., Novielli A., Bhargava P., Hayes D. F., Desta Z., Flockhart D. A. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 2003; 95: 1758–1764
   PubMed Web of Science ®Google Scholar
• Thurlimann B., Keshaviah A., Coates A. S., Mouridsen H., Mauriac L., Forbes J. F., Paridaens R., Castiglione-Gertsch M., Gelber R. D., Rabaglio M., Smith I., Wardley A., Price K. N., Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 2005; 353: 2747–2757
   PubMed Web of Science ®Google Scholar
• Townsend D. M., Tew K. D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003; 22: 7369–7375
   PubMed Web of Science ®Google Scholar
• van't Veer L. J., Dai H., van de Vijver M. J., He Y. D., M. Hart A. A., Mao M., Peterse H. L., van der Kooy K., Marton M. J., Witteveen A. T., Schreiber G. J., M K. R., Roberts C., Linsley P. S., Bernards R., Friend S. H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530–536
   PubMed Web of Science ®Google Scholar
• van de Vijver M. J., He Y. D., van ’t Veer L. J., Dai H., Hart A. A. M., Voskuil D. W., Schreiber G. J., Peterse J. L., Roberts C., Marton M. J., Parrish M, Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E. T., Friend S. H., Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002; 347: 1999–2009
   PubMed Web of Science ®Google Scholar
• Watters J. W., Kraja A., Meucci M. A., Province M. A., McLeod H. L. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc. Natl. Acad. Sci. USA 2004; 101: 11809–11814
   PubMed Web of Science ®Google Scholar